Published in J Urol on November 01, 1999
A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor. Nat Rev Cancer (2015) 1.40
Endocrine tumours in neurofibromatosis type 1, tuberous sclerosis and related syndromes. Best Pract Res Clin Endocrinol Metab (2010) 1.35
The approach to the patient with paraganglioma. J Clin Endocrinol Metab (2009) 1.30
Advances in the treatment of neurofibromatosis-associated tumours. Nat Rev Clin Oncol (2013) 1.26
Paragangliomas and paraganglioma syndromes. GMS Curr Top Otorhinolaryngol Head Neck Surg (2012) 1.03
Pheochromocytoma associated with neurofibromatosis type 1: concepts and current trends. World J Surg Oncol (2010) 0.96
Neoplasms associated with germline and somatic NF1 gene mutations. Oncologist (2012) 0.95
Pheochromocytoma in von Hippel-Lindau disease and neurofibromatosis type 1. Fam Cancer (2005) 0.94
Adrenalectomy for familial pheochromocytoma in the laparoscopic era. Ann Surg (2002) 0.93
Age at diagnosis of pheochromocytoma differs according to catecholamine phenotype and tumor location. J Clin Endocrinol Metab (2010) 0.92
Pheochromocytoma and paraganglioma. Prog Brain Res (2010) 0.91
Paragangliomas/Pheochromocytomas: clinically oriented genetic testing. Int J Endocrinol (2014) 0.89
An update on the genetics of pheochromocytoma. J Hum Hypertens (2012) 0.87
Genetic testing for pheochromocytoma. Curr Hypertens Rep (2010) 0.87
Advances in biochemical screening for phaeochromocytoma using biogenic amines. Clin Biochem Rev (2009) 0.87
Zollinger-Ellison syndrome associated with neurofibromatosis type 1: a case report. BMC Cancer (2005) 0.84
The genetic basis of pheochromocytoma and paraganglioma: implications for management. Urology (2014) 0.83
Familial pheochromocytomas and paragangliomas. Mol Cell Endocrinol (2013) 0.83
Role of hypoxia and HIF2α in development of the sympathoadrenal cell lineage and chromaffin cell tumors with distinct catecholamine phenotypic features. Adv Pharmacol (2013) 0.80
Glioblastoma in a patient with neurofibromatosis type 1: a case report and review of the literature. Brain Tumor Res Treat (2014) 0.80
Suprarenal solitary fibrous tumor associated with a NF1 gene mutation mimicking a kidney neoplasm: implications for surgical management. World J Surg Oncol (2014) 0.79
Neurofibromatosis 1 with pheochromocytoma. Indian J Endocrinol Metab (2011) 0.79
Perioperative management of neurofibromatosis type 1. Ochsner J (2012) 0.79
A Novel Medical Treatment of Cushing's Due to Ectopic ACTH in a Patient With Neurofibromatosis Type 1. Int J Endocrinol Metab (2012) 0.78
Adrenal disorders and the paediatric brain: pathophysiological considerations and clinical implications. Int J Endocrinol (2014) 0.78
Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis. Endocrinol Diabetes Metab Case Rep (2014) 0.78
Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case. BMC Cancer (2015) 0.78
Type 1 neurofibromatosis and pheochromocytoma: Focus on hypertension. J Neurosci Rural Pract (2012) 0.77
Spontaneous rupture of adrenal pheochromocytoma in a patient with Von Recklinghausen's disease. Indian J Crit Care Med (2009) 0.77
P.Arg82Leu von Hippel-Lindau (VHL) gene mutation among three members of a family with familial bilateral pheochromocytoma in India: molecular analysis and in silico characterization. PLoS One (2013) 0.76
Neurofibromatosis with bilateral renal artery stenosis and end stage renal disease: case report. Sultan Qaboos Univ Med J (2009) 0.75
Genotype-Phenotype Correlation in Patients With Germline Mutations of VHL, RET, SDHB, and SDHD Genes: Thai Experience. Clin Med Insights Endocrinol Diabetes (2017) 0.75
[Contribution of clinical guidance in the diagnosis of endocrine arterial hypertension]. Pan Afr Med J (2014) 0.75
fdg-pet in two cases of neurofibromatosis type 1 and atypical malignancies. Curr Oncol (2014) 0.75
Pheochromocytoma associated with von Hippel-lindau disease in a Pakistani family. Urol Ann (2015) 0.75
Rupture of the Left External Iliac Artery and Right Groin Pseudoaneurysm Formation following Angioplasty in a Patient with Neurofibromatosis Type 1 and Undiagnosed Bilateral Phaeochromocytoma. Case Rep Radiol (2013) 0.75
The NF1 somatic mutational landscape in sporadic human cancers. Hum Genomics (2017) 0.75
Neurofibromatosis type 1 associated with pheochromocytoma and gastrointestinal stromal tumors: A case report and literature review. Oncol Lett (2016) 0.75
Breast cancer in neurofibromatosis type 1: overrepresentation of unfavourable prognostic factors. Br J Cancer (2016) 0.75
Pheochromocytoma and Neurofibromatosis Type 1 in a Patient with Hypertension. Open Access Maced J Med Sci (2015) 0.75
A resected case of liver metastases from extra-adrenal retroperitoneal paraganglioma with von Recklinghausen's disease 16 years after the initial surgery. Surg Case Rep (2015) 0.75
Apogossypolone (ApoG2) induces ROS-dependent apoptosis and reduces invasiveness of PC12 cells in vitro and in vivo. Am J Transl Res (2017) 0.75
Update on Modern Management of Pheochromocytoma and Paraganglioma. Endocrinol Metab (Seoul) (2017) 0.75
Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci U S A (1994) 8.47
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation. N Engl J Med (2000) 4.99
Chlamydial infection. Results of micro-immunofluorescence tests for the detection of type-specific antibody in certain chlamydial infections. Br J Vener Dis (1972) 4.50
Inhibition of transcription elongation by the VHL tumor suppressor protein. Science (1995) 4.23
Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene. Proc Natl Acad Sci U S A (1996) 3.88
The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins. Proc Natl Acad Sci U S A (1997) 3.75
Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg (1989) 3.58
Defective placental vasculogenesis causes embryonic lethality in VHL-deficient mice. Proc Natl Acad Sci U S A (1997) 3.27
Histopathology of benign versus malignant sympathoadrenal paragangliomas: clinicopathologic study of 120 cases including unusual histologic features. Hum Pathol (1990) 3.22
Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene (1999) 3.01
Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem (1986) 2.95
Small (< or = 3-cm) renal masses: detection with CT versus US and pathologic correlation. Radiology (1996) 2.90
BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dubé syndrome: a new series of 50 families and a review of published reports. J Med Genet (2008) 2.79
Birt-Hogg-Dubé syndrome, a genodermatosis associated with spontaneous pneumothorax and kidney neoplasia, maps to chromosome 17p11.2. Am J Hum Genet (2001) 2.68
Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma. Biochim Biophys Acta (1996) 2.64
Improved detection of germline mutations in the von Hippel-Lindau disease tumor suppressor gene. Hum Mutat (1998) 2.64
Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med (1996) 2.61
A microdissection technique for archival DNA analysis of specific cell populations in lesions < 1 mm in size. Am J Pathol (1995) 2.59
The consequences of chromosomal aneuploidy on gene expression profiles in a cell line model for prostate carcinogenesis. Cancer Res (2001) 2.51
Trisomy 7-harbouring non-random duplication of the mutant MET allele in hereditary papillary renal carcinomas. Nat Genet (1998) 2.50
The t(X;1)(p11.2;q21.2) translocation in papillary renal cell carcinoma fuses a novel gene PRCC to the TFE3 transcription factor gene. Hum Mol Genet (1996) 2.45
Recent advances in genetics, diagnosis, localization, and treatment of pheochromocytoma. Ann Intern Med (2001) 2.45
von Hippel-Lindau disease: genetic, clinical, and imaging features. Radiology (1995) 2.38
Fusion of splicing factor genes PSF and NonO (p54nrb) to the TFE3 gene in papillary renal cell carcinoma. Oncogene (1997) 2.32
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer. Clin Cancer Res (2001) 2.05
Reduction of renal function by newer nonsteroidal anti-inflammatory drugs. Am J Med (1978) 1.96
Pheochromocytomas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocrinol Metab (2001) 1.91
Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst (1993) 1.91
Hereditary papillary renal cell carcinoma. J Urol (1994) 1.87
Novel mutations in FH and expansion of the spectrum of phenotypes expressed in families with hereditary leiomyomatosis and renal cell cancer. J Med Genet (2005) 1.85
Allelic loss on chromosome 8p12-21 in microdissected prostatic intraepithelial neoplasia. Cancer Res (1995) 1.85
Renal cancer in families with hereditary renal cancer: prospective analysis of a tumor size threshold for renal parenchymal sparing surgery. J Urol (1999) 1.84
Molecular markers of neuroendocrine development and evidence of environmental regulation. Proc Natl Acad Sci U S A (1987) 1.84
Continuous measurement of tissue blood flow by laser-Doppler spectroscopy. Am J Physiol (1977) 1.82
Evidence of independent origin of multiple tumors from patients with prostate cancer. J Natl Cancer Inst (1998) 1.81
Predictive value of preoperative tests in discriminating bilateral adrenal hyperplasia from an aldosterone-producing adrenal adenoma. J Clin Endocrinol Metab (2000) 1.80
Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p12-21. Cancer Res (1996) 1.78
Comparative genomic analysis of tumors: detection of DNA losses and amplification. Proc Natl Acad Sci U S A (1995) 1.75
Increased incidence of isoniazid hepatitis in rapid acetylators: possible relation to hydranize metabolites. Clin Pharmacol Ther (1975) 1.75
von Hippel-Lindau gene deletion detected in the stromal cell component of a cerebellar hemangioblastoma associated with von Hippel-Lindau disease. Hum Pathol (1997) 1.74
Decreased taste sensitivity after D-penicillamine reversed by copper administration. Lancet (1967) 1.69
Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET proto-oncogene. Cancer Res (1998) 1.66
Nuclear/cytoplasmic localization of the von Hippel-Lindau tumor suppressor gene product is determined by cell density. Proc Natl Acad Sci U S A (1996) 1.66
Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med (1999) 1.65
Iodine-131-metaiodobenzylguanidine scintigraphy in preoperative and postoperative evaluation of paragangliomas: comparison with CT and MRI. J Nucl Med (1993) 1.65
Plasma metanephrines in the diagnosis of pheochromocytoma. Ann Intern Med (1995) 1.64
Sipple's syndrome: medullary thyroid carcinoma, pheochromocytoma, and parathyroid disease. Studies in a large family. NIH conference. Ann Intern Med (1973) 1.64
Evaluation of the initial care of hypertensive patients. JAMA (1971) 1.64
Allelic deletions of the VHL gene detected in multiple microscopic clear cell renal lesions in von Hippel-Lindau disease patients. Am J Pathol (1996) 1.64
Endolymphatic sac tumors. A source of morbid hearing loss in von Hippel-Lindau disease. JAMA (1997) 1.63
The von Hippel-Lindau tumor suppressor gene inhibits hepatocyte growth factor/scatter factor-induced invasion and branching morphogenesis in renal carcinoma cells. Mol Cell Biol (1999) 1.62
Characterization of the VHL tumor suppressor gene product: localization, complex formation, and the effect of natural inactivating mutations. Proc Natl Acad Sci U S A (1995) 1.61
Bartter's syndrome: a disorder characterized by high urinary prostaglandins and a dependence of hyperreninemia on prostaglandin synthesis. Am J Med (1976) 1.55
Validity and reliability of liquid chromatography with electrochemical detection for measuring plasma levels of norepinephrine and epinephrine in man. Life Sci (1981) 1.55
Molecular and cellular characterization of human renal cell carcinoma cell lines. Cancer Res (1992) 1.52
Effects of polymerization on the hypertensive action of diaspirin cross-linked hemoglobin in rats. J Lab Clin Med (1997) 1.52
Hereditary and sporadic papillary renal carcinomas with c-met mutations share a distinct morphological phenotype. Am J Pathol (1999) 1.52
Multiple neuroendocrine tumors of the pancreas in von Hippel-Lindau disease patients: histopathological and molecular genetic analysis. Am J Pathol (1998) 1.51
Somatic allelic deletion of nm23 in human cancer. Cancer Res (1991) 1.50
Loss of annexin 1 correlates with early onset of tumorigenesis in esophageal and prostate carcinoma. Cancer Res (2000) 1.50
Prostaglandin biosynthesis by rabbit renomedullary interstitial cells in tissue culture. Stimulation by angiotensin II, bradykinin, and arginine vasopressin. J Clin Invest (1977) 1.50
Unexplained excess risk of bladder cancer in men. J Natl Cancer Inst (1990) 1.49
Determination of metanephrines in plasma by liquid chromatography with electrochemical detection. Clin Chem (1993) 1.47
Loss of heterozygosity and somatic mutations of the VHL tumor suppressor gene in sporadic cerebellar hemangioblastomas. Cancer Res (1998) 1.46
Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J Clin Oncol (1988) 1.46
Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol (1989) 1.46
Laparoscopic adrenalectomy: a new standard of care. Urology (1997) 1.46
Human amyloid protein: chemical variability and homogeneity. J Histochem Cytochem (1971) 1.45
Parenchymal sparing surgery in patients with hereditary renal cell carcinoma: 10-year experience. J Urol (2001) 1.45
Loss of heterozygosity on chromosome 13 is associated with advanced stage prostate cancer. J Urol (1999) 1.41
Plasma dihydroxyphenylglycol and the intraneuronal disposition of norepinephrine in humans. J Clin Invest (1988) 1.41
Utilization of microdissection and the polymerase chain reaction for the diagnosis of adrenal cortical carcinoma in fine-needle aspiration cytology. Cancer (1999) 1.39
Collagen synthesis in human keloid and hypertrophic scar. Surg Forum (1971) 1.38
Pancreatic neuroendocrine tumors associated with von Hippel Lindau disease: diagnostic and management recommendations. Surgery (1998) 1.38
Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene (1999) 1.38
Molecular analysis of genetic changes in the origin and development of renal cell carcinoma. Cancer Res (1991) 1.38
Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine. Ann Intern Med (1988) 1.37
Mosaicism in von Hippel-Lindau disease: lessons from kindreds with germline mutations identified in offspring with mosaic parents. Am J Hum Genet (2000) 1.33
Elevated urinary prostaglandins and the effects of aspirin on renal function in lupus erythematosus. Ann Intern Med (1978) 1.33
Effects of dietary sodium and of acute saline infusion on the interrelationship between dopamine excretion and adrenergic activity in man. J Clin Invest (1974) 1.32
Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium-retaining steroids. Circ Res (1974) 1.31
VHL gene deletion and enhanced VEGF gene expression detected in the stromal cells of retinal angioma. Arch Ophthalmol (1999) 1.31
The influence of sympathetic activity and isoprenaline on the secretion of amylase from the human parotid gland. Arch Oral Biol (1974) 1.30
Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg (1992) 1.29
Pheochromocytoma: evaluation, diagnosis, and treatment. World J Urol (1999) 1.29
HIF and fumarate hydratase in renal cancer. Br J Cancer (2007) 1.27
The natural history of renal lesions in von Hippel-Lindau disease: a serial CT study in 28 patients. AJR Am J Roentgenol (1992) 1.27
Urinary kallikrein excretion in normal man. Relationships to sodium intake and sodium-retaining steroids. Circ Res (1974) 1.25
Provocative agents and the diagnosis of medullary carcinoma of the thyroid gland. Ann Surg (1978) 1.25
Medullary thyroid carcinoma: relationship of method of diagnosis to pathologic staging. Ann Surg (1978) 1.25
Prevalence of microscopic tumors in normal appearing renal parenchyma of patients with hereditary papillary renal cancer. J Urol (2000) 1.24